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We have constructed recombinant DNA plasmids which carry both the aminoglycoside phosphotransferase (aph) gene 
and the chloramphenicol acetyl-transferase (CAT) gene linked to the human normal or mutant T24 H-rasl promoter. 
We have transfected these plasmids into rat 208F fibroblasts using the calcium phosphate technique and selected for stable 
transformants by geneticin resistance. These transformants expressed CAT activity at low levels. However, when treated 
with the phorbol ester TPA, CAT levels increased substantially. Cells transfected with recombinant plasmids carrying 
a promoterless CAT gene did not respond to TPA. We have noted four motifs in the H-rasl promoter region which 
resemble TPA-inducible and AP-l-binding consensus equences. We suggest hat AP-l-like proteins may play a role in 
control of H-rasl transcription. 
H-rasl Promoter; Phorbol ester 
1. INTRODUCTION 
The development of cancer is widely accepted to 
be a multistage process (for review see [l]). More- 
over, it has been suggested that the specific bio- 
logical change that takes place during tumor 
initiation and progression may be a consequence of 
the activation of cellular proto-oncogenes by 
genetic or epigenetic events [l]. 
Phorbol esters such as TPA (12-O-tetradeca- 
noylphorbol-13-acetate) are tumor promoters 
which are capable of potentiating the effect of an 
initiating carcinogen [2]. It is thought that they ex- 
ert their biological effect by altering gene expres- 
sion through a process which involves the activa- 
tion of protein kinase C [3]. Relevant to this 
hypothesis is the finding that TPA induces tran- 
scription of cellular proto-oncogenes, e.g. c-jios 
[4,5], c-myc [4,6] and c-sis [7]. TPA can also in- 
Correspondence address: D.A. Spandidos, Biological Research 
Center, National Hellenic Research Foundation, 48 Vas. Con- 
stantinou Avenue, Athens 11635, Greece 
duce the expression of collagenase [8] and 
stromelysin [8,9]. These genes have been im- 
plicated in tumor invasiveness and metastasis [lo] 
and in angiogenesis [l l] and are known to carry 
TPA-inducible elements in their promoter [12]. 
It has been shown that quantitative and/or 
qualitative changes in ras gene expression are 
responsible for triggering various steps of cell 
transformation, i.e. immortalization, tumorigeni- 
city and metastasis (for review see [13]). In addi- 
tion ras expression can trigger fos expression [14] 
and can induce a number of growth factors in- 
cluding transforming growth factors (for review 
see [15]) and IL-3 like activity [ 161. 
The regulation of H-rasl gene expression is not 
completely understood although a number of 
transcriptional regulatory elements have been 
described at both the 5 ’ - [ 17-191 and 3 ‘-end [20] 
of the gene. Regulatory sequences have also been 
found in the first [21] and fourth [22] intron of the 
H-rasl gene. In the first case a six base pair dele- 
tion in the first intron of the T24 H-rasl gene in- 
creases transcriptional activity from the H-rasl 
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promoter [21] whereas in the latter case a point 
mutation in the fourth intron is responsible for in- 
creased expression and transforming activity of the 
oncogene [22]. Moreover, it has been suggested 
that the regulation of H-rasl transcription may in- 
volve the Spl transcriptional factor since a number 
of Spl-binding sites have been found in the pro- 
moter region [23]. 
The transcription factor AP-1 (activator protein 
1) stimulates transcription in vitro and binds 
specifically to the sequence TGACTA in both the 
human metallothionein (hMTIIA) and the SV40 
enhancer regions [24]. Several TPA-inducible 
elements contain a common sequence TGAG- 
TCAG [12]. Recent studies suggest hat AP-1 in- 
teracts with TPA-inducible elements in hMTIIA, 
SV40 and collagenase genes as determined by 
direct DNA-binding studies of wild type and mu- 
tant templates [24]. Thus AP-1 appears to be one 
of the cellular transcription factors whose activity 
may be modulated by TPA. 
We have noted four sequences in the H-rasl pro- 
moter which resemble the consensus equence for 
TPA-inducible and AP-l-binding sequences. We 
therefore tested if this promoter could be activated 
by TPA. Our results showed that TPA can indeed 
induce expression of a CAT gene linked to the 
human H-rasl promoter region. 
2. MATERIALS AND METHODS 
2.1. Recombinant plasmids 
The organization of the human H-rasl gene with emphasis on 
the promoter region contained within the 843 bp SstI fragment 
is shown in fig. I. Construction of plasmids p20lA and p202A 
carrying the aph gene and the CAT gene linked to the human 
H-rasl promoter region (843 bp SstI fragment) is described in 
fig.2. The figure also shows the control plasmid p22OA which 
carries a promoterless CAT gene linked to the aph gene. 
2.2. DNA transfection and CAT assays 
Transfections of rat 208F cells with plasmid DNA were per- 
formed using a modification [26] of the calcium phosphate 
technique [27]. Stable transfectants were isolated in the 
presence of 200 pg/ml geneticin. For CAT assays, cells grew ex- 
ponentially in the absence of geneticin. TPA was purchased 
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Fig.1. Organization of the human H-rasl gene. The nucleotide sequence is taken from Capon et al. [2S]. The coding sequences are 
designated by black boxes and the non-coding 5 ’ -sequences by open boxes. The variable tandem repeat (VTR) is indicated by a hatched 
box and the transcriptional orientation by an arrow. The transcriptional start sites at positions 291 and 372 were determined by SI 
mapping [19] and at positions 537, 549, 559 and 561 by primer extension [17]. Position 441 indicates the start of homology with the 
v-ras oncogene. The sequences resembling the TPA-responsive and AP-l-binding consensus equence at positions 259, 309, 320 and 
424 are shown. Homologies with TPA-responsive sequences are shown with lines above and with AP-l-binding sequence with lines 
below the nucleotides. I, II, III and IV, coding exons; la, non-coding exon. 
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Fig.2. Structure of uph recombinant plasmids used to transfect 
the rat 208F cells. The 1.9 kb Hind111 fragment carrying the 
uph gene under the HSV-I thymidine kinase promoter and 
3’-polyadenylation signal was derived from plasmid ~25 
(obtained from Jas Lang) was inserted into the single Hind111 
site of plasmids pCAT122A and pCATl23A. The junction 
between aph and CAT genes occurs between the HSV-1 rk and 
the HSV-2 immediate early 5 gene 3’-polyadenylation se- 
quences linked to the uph and CAT genes. Plasmids pCATl22A 
and pCAT123A carry the CAT gene linked to the normal and 
mutant T24 H-rusl gene promoter, respectively, and they have 
been previously described [18]. Plasmid p21OA was constructed 
by inserting the 1.9 kb Nindlll fragment carrying the uph gene 
into the single Hind111 site of plasmid pCAT12 [18]. Dashed 
line, plasmid sequences; thin line, CAT and aph genes; thick 
line, H-rusl sequences; open box, non-coding H-rusl exon; H, 
HindIll; S, WI. Arrows indicate transcriptional orientation. 
from Sigma and 1000 x stocks were made in DMSO. Cells in 
the presence or absence of TPA were harvested and assayed for 
CAT activity as previously described [18]. 
3. RESULTS 
Since the T(IS gene and phorbol esters are known 
to co-operate in cell transformation in vivo [28] or 
in vitro [29], it was of interest to examine the 
responsiveness of H-rasl promoter to TPA. The 
possibility that the human H-rasl promoter could 
respond to the phorbol ester TPA was examined by 
treating transfectants carrying a CAT gene linked 
to the ras promoter. 
Maps are not drawn to scale. Transfectant cell lines were obtained by trans- 
TPA - + - + - + 
CELLS RF201A-l RF220A-1 RF202A-1 
Fig.3. Chromatograms for representative CAT assays with 
extracts from recipient 208F and transfectant cell lines with 
(50 ng/ml) and without treatment with TPA. 
Table 1 
Relative values of CAT activity in transfectant rat 208F fibroblasts 
CeW Transfected Promote? TPA’ CAT activity Fold 
plasmidb (average * SD)d increase 
RF220A-1 p22OA - - 1.0 - 
RF220A- 1 p220A - + l.OkO.2 - 
RFZOIA-1 p201A H-rusl _ 2.5 + 0.3 1.0 
RF201A-1 p201A H-rusl + 38 f 2.5 15.2 
RF202A- 1 p202A T24 H-rasl - 4.2 k 0.4 1.0 
RF202A-1 p202A T24 H-rusl + 51 + 3.2 12.1 
’ Rat 208F recipient and transfectant RF201A-1, RFZOlB-I and RF220A-1 cell 
lines were derived as described in section 2 
b See fig.2 for plasmid constructions 
’ Cells treated with 50 ng/ml TPA for I2 h at 37°C 
d Relative values of CAT activity in each cell line vs that obtained in RF201A 
in the absence of TPA. The value for CAT activity in RF2OlA cells was 
8.5 x 10m4 pmol acetylated chloramphenicol/Fg protein per h incubation. 
Average + SD from three experiments 
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fecting plasmids p201A, p202A and p220A (see 
figs 1 and 2 for details) into recipient 208F cells 
and selecting for geneticin resistance. As seen in 
fig.3 the exogenous CAT gene is expressed at low 
levels. 
Treatment with TPA was performed at various 
TPA concentrations and time intervals. At op- 
timum conditions, that is, after 12 h exposure to 
50 ng TPA/ml, CAT expression in RF201A and 
RF202A transfectants which carried CAT plasmids 
linked to the normal and T24 H-rasl promoters, 
respectively, was substantially increased (15.2-fold 
increase with the normal and 12.1-fold increase 
with the mutant T24 promoter, respectively) over 
untreated cells (fig.3 and table 1). On the other 
hand cells transfected with recombinant plasmid 
p22OA, which carries a promoterless CAT gene did 
not respond to TPA (table 1). Moreover, the 
response of the H-rasl promoter to TPA was the 
same when cell lines transfected with recombinant 
plasmids p201B, p202B and p220B carrying the 
aph gene in the opposite orientation relative to the 
CAT gene were employed (not shown). 
4. DISCUSSION 
The mechanism by which the various control 
elements of H-rasl promoter operate to trigger 
RNA synthesis still remains to be determined. 
However, it is obvious that an important step 
towards understanding the function of these 
transcription regulatory elements is the biological 
characterization of the cellular proteins which in- 
teract with them. 
It is possible that TPA-inducible elements are 
regulated by posttranslational modification of pre- 
existing transcriptional factors which are already 
present in the cell [30]. Nishizuka [3] has suggested 
that alteration of gene expression by TPA involves 
a cascade of events triggered by the action of pro- 
tein kinase C. 
When v-ras genes from Harvey and BALB 
murine sarcoma viruses are introduced into epider- 
ma1 cells in vivo they can act as initiators of two- 
stage mouse skin carcinogenesis. Treatment with 
TPA induced benign papillomas some of which 
progressed to invasive carcinomas [28]. 
The complete dependence on TPA treatment for 
tumor development suggested that a critical in- 
teraction must take place between the Ha-MSV- 
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initiated cell and TPA [28]. Several explanations 
have been put forward for the observed synergism 
between ras gene activation and TPA treatment. 
Stimulation of cell growth by TPA occurs through 
direct interaction with protein kinase C [3 11. Alter- 
natively, both ras p21 and TPA could be involved 
in signal transduction perhaps through phospho- 
inositide turnover [32] or the epidermal growth 
factor receptor system [33,34]. 
TPA treatment is also known to cause increased 
cellular proliferation and elevated myc expression 
[35,36]. A co-operative effect between TPA and 
transfected ras genes in the transformation of 
primary fibroblasts in vitro has also been observed 
[29]. In this paper we investigate if TPA actually 
affects expression of the H-rasl gene. We show 
that in stably transfected rat, fibroblasts, TPA in- 
duces expression of the reporter CAT gene cova- 
lently linked to the H-rasl promoter. It is of 
interest that the H-rasl promoter region carries 4 
motifs resembling the consensus sequences of 
TPA-inducible and AP-1 -binding elements (fig. 1). 
Although these experiments do not prove that the 
effect of TPA is mediated through protein/DNA 
interactions at these motifs, this is a possibility that 
we are currently testing. 
It has been found recently that the transcription 
factor AP-1 forms a complex with thefos encoded 
protein and they share a common ,DNA-binding 
site [37]. Moreover, the transcription factor AP-1 
is homologous to the proto-oncogene jun [38]. 
Thus, it is possible that both the fos and jun pro- 
tein products bind to the H-rasl promoter and 
regulate transcription of the H-rasl gene. This is 
also being tested. Finally, it is also of interest that 
fos can be induced by microinjecting ras p21 [39] 
and that truncated ras genes can still transform 
cells [40]. 
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